HomepageHPX • FRA
add
Hisamitsu Pharmaceutical Co Inc
Vorige slotkoers
€ 25,60
Dag-range
€ 25,80 - € 25,80
Jaar-range
€ 21,00 - € 28,80
Beurswaarde
364,25Â mld. JPY
Gem. volume
6,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | aug 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 39,65Â mld. | 13,66% |
Bedrijfskosten | 18,75Â mld. | 17,95% |
Netto inkomsten | 4,31Â mld. | -1,33% |
Netto winstmarge | 10,87 | -13,18% |
Winst per aandeel | — | — |
EBITDA | 6,35Â mld. | 20,49% |
Effectief belastingtarief | 28,38% | — |
Balans
Totale activa
Totale passiva
(JPY) | aug 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 122,74Â mld. | -13,22% |
Totale activa | 350,48Â mld. | 1,79% |
Totale passiva | 74,55Â mld. | 7,74% |
Totaal aandelenvermogen | 275,92 mld. | — |
Uitstaande aandelen | 73,34 mln. | — |
Koers-boekwaardeverhouding | 0,01 | — |
Rendement op activa | 3,52% | — |
Rendement op kapitaal | 4,46% | — |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | aug 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 4,31Â mld. | -1,33% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Opgericht
1847
Hoofdvestiging
Website
Werknemers
2.759